Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins.

Authors :: Dwojak M
Bobrowicz M
Bil J
Bojarczuk K
Pyrzynska B
Siernicka M
Malenda A
Lech-Maranda E
Tomczak W
Giannopoulos K
Golab J
Winiarska M
Source :: Blood cancer journal [Blood Cancer J] 2015 Apr 10; Vol. 5, pp. e300. Date of Electronic Publication: 2015 Apr 10.
Publication Year :: 2015

Subjects :: Antibodies, Monoclonal, Humanized
Complement System Proteins biosynthesis
Complement System Proteins genetics
Gene Expression Regulation, Leukemic drug effects
Humans
Leukemia, Lymphocytic, Chronic, B-Cell genetics
Leukemia, Lymphocytic, Chronic, B-Cell pathology
Niacinamide administration & dosage
Rituximab
Sorafenib
Antibodies, Monoclonal administration & dosage
Antibodies, Monoclonal, Murine-Derived administration & dosage
Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
Niacinamide analogs & derivatives
Phenylurea Compounds administration & dosage

Full Text Access

Tools